Long-Term Survivors with EGFR Wild-Type Advanced NSCLC Treated with Second-Line Erlotinib: Subgroup Analysis from WILT Study

被引：0

作者：

De Castro, Javier ^{[1
]}

Bernabe, Reyes ^{[2
]}

Angeles Sala, M. ^{[3
]}

Puente, Javier ^{[4
]}

Vazquez, Sergio ^{[5
]}

Majem, Margarita ^{[6
]}

Rosario Garcia-Campelo, M. ^{[7
]}

Paredes, Alfredo ^{[8
]}

Lopez, Rafael ^{[9
]}

Girones, Regina ^{[10
]}

Diz, Pilar ^{[11
]}

Gomez-Codina, Jose ^{[12
]}

Triguboff, Alberto ^{[13
]}

Terrancle, Angeles ^{[14
]}

Gordo, Rocio ^{[14
]}

机构：

[1] Hosp Univ La Paz, Madrid, Spain

[2] Hosp Univ Valme, Seville, Spain

[3] Hosp Univ Basurto, Bilbao, Spain

[4] Hosp Clin San Carlos, Madrid, Spain

[5] Hosp Univ Lucus Augusti, Lugo, Spain

[6] Hosp La Santa Creu & St Pau, Barcelona, Spain

[7] Complejo Hosp Univ A Coruna, La Coruna, Spain

[8] Hosp Donostia, San Sebastian, Spain

[9] Hosp Clin Valladolid, Valladolid, Spain

[10] Hosp Lluis Alcanyis Xativa, Valencia, Spain

[11] Complejo Asistencial Univ Leon, Leon, Spain

[12] Hosp Univ & Politecn La Fe, Valencia, Spain

[13] Hosp Comarcal Melilla, Melilla, Spain

[14] Roche Farma SA, Madrid, Spain

来源：

JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期

关键词：

Long-term; survivors; wild-type; Erlotinib;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ORAL32.02

引用

收藏

页码：S235 / S235

页数：1

相关论文

empty

未找到相关数据